Novo Nordisk A/S, a leading healthcare company, has filed its Specialized Disclosure Report (Form SD) with the United States Securities and Exchange Commission. The report, which covers the period from January 1 to December 31, 2023, details the company's compliance with Rule 13p-1 under the Securities Exchange Act concerning conflict minerals. The Conflict Minerals Report, which is a key component of the filing, is available for public access on Novo Nordisk's website. This annual disclosure is part of the company's commitment to sustainable business practices and governance. The report was signed by Executive Vice President & Chief Financial Officer, Karsten Munk Knudsen, on May 17, 2024.

Novo Nordisk A/S, a leading healthcare company, has filed its Specialized Disclosure Report (Form SD) with the United States Securities and Exchange Commission. The report, which covers the period from January 1 to December 31, 2023, details the company's compliance with Rule 13p-1 under the Securities Exchange Act concerning conflict minerals. The Conflict Minerals Report, which is a key component of the filing, is available for public access on Novo Nordisk's website. This annual disclosure is part of the company's commitment to sustainable business practices and governance. The report was signed by Executive Vice President & Chief Financial Officer, Karsten Munk Knudsen, on May 17, 2024.